Presentations & Abstracts

Presentation & Abstract
Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
Kim M, Parmar H, Aryal M, Schipper M, Devasia T, Kesari S, Morikawa A, et al.
Society for NeuroOncology (SNO) 23rd Annual Meeting, Nov 15th-18th 2018, New Orleans, LA

 

Presentation & Abstract
RRx-001 is a phase 3-ready small molecule which immunonormalizes the tumor microenvironment
Cabrales P, Carter C, Oronsky B, Reid T
Society for Immunotherapy of Cancer (SITC) Annual Meeting, Nov 7-11 2018, Washington DC

Presentation & Abstract
BETATRAP, a replication competent type 5 adenovirus carrying a TGF-beta trap, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model
Larson C, Reid T, Carter C, Oronsky B
Society for Immunotherapy of Cancer (SITC) Annual Meeting, Nov 7-11 2018, Washington DC

Presentation & Abstract
Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
Kim M.
60th ASTRO Annual Meeting – American Society for Radiation Oncology (ASTRO), Oct 22nd 2018, San Antonio, TX

Presentation & Abstract
Radioprotective effects of RRx-001 on the pathophysiology of the hematopoietic system using a murine radiation model
Kimberly J. Jurgensen, Lynnette H. Cary, Thomas A. Summers, Corey A. Carter, William K. J. Skinner
2017 Radiation Research Society Annual Meeting, Cancun, MX

Presentation & Abstract
Restoring efficacy of immunotherapy treatments in oncology with radical oxygen and nitrogen based epigenetic drugs
Scicinski J.
Invited Presentation at Stem Cells Regenerative Medicine Congress 2015, Washington, D.C., September 2 – 3, 2015AACR, Chromatin and Epigenetics in Cancer, 2015, Atlanta, GA, September 24 – 27, 2015

Presentation & Abstract
RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models
Raghunand N, Scicinski J, Oronsky B, Jagadish B, Mash E, Korn R.
ISMRM 2015

Presentation & Abstract
The development of RRx-001, a novel nitric-oxide-mediated epigenetically active anticancer agent
Scicinski J, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Reid T.
Invited Presentation at 4th International Workshop on Nitric Oxide in Cancer Therapy, Mar 13 – 14, 2015, Seville, Spain

Presentation & Abstract
Early results from a phase 2 study of RRx-001, a novel epigenetic modulator, show resensitization to irinotecan in colorectal cancer
Reid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J.
5th Clinical Epigenetics International Meeting. March 5th – 6th, 2015 – Düsseldorf, Germany

Presentation & Abstract
Early results: “ROCKET” a phase II study of RRx-001, a novel triple epigenetic inhibitor, resensitization to irinotecan in colorectal cancer
Carter C, Reid T, Fisher G, Cho-Phan C, Kunz P, Kaiser H, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J.
13th International Congress on Targeted Anticancer Therapies: TAT 2015. Paris, France, mar 2-4, 2015

Presentation & Abstract
RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the phase 2 “ROCKET” study
Reid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Scicinski J.
17th Annual Symposium on Anti-Angiogenesis and immune therapies, La Jolla, Feb 19 – 21, 2015

Presentation & Abstract
RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study
Reid T, Carney J, Beale K, Chan C, Nguyen H, Stirn M, Ning S, Knox S, Oronsky B, Scicinski J, Caroen S, Parker C, Fanger G, Fisher G.
AACR Translation of the Cancer Genome Conference, San Francisco, California, February 7 – 9, 2015

Presentation & Abstract
Anti-myeloma activity of a novel free radical inducer RRx-001
Das D , Tian Z , Ray A , Ravillah D, Song Y, Richardson P, Oronsky B, Scicinski J, Chauhan D, Anderson K.
Blood, 2014, 124 (21) 4712

Presentation & Abstract
RRx-001 an EXO-based epigenetic anti-cancer agent in phase 2 clinical trials
Cabrales P, Reid T, Oronsky B, Scicinski J, Chauchan D, Parker C, Caroen S, Fanger G.
ISEV2014 Educational Event: Extracellular Vesicles and Biofluid Biopsies/Companion Diagnostics Conference

Presentation & Abstract
A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent
Reid T, Oronsky B, Infante J, Burris H, Scribner C, Knox S, Stephens J, Fanger G, Scicinski J.
J Clin Oncol 2014 32:5s (suppl; abstr 2578)

Presentation & Abstract
RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models
Raghunand N, Scicinski J, Oronsky B, Guntle G, Bruckheimer E, Korn R.
Proceedings: AACR 105th Annual Meeting 2014– Apr 5-9, 2014; San Diego, CA, Abstr 2068

Presentation & Abstract
RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase
Cabrales P, Oronsky B, Scicinski J.
Proceedings: AACR 105th Annual Meeting 2014– Apr 5-9, 2014; San Diego, CA, Abstr 1420

Presentation & Abstract
Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice
Ning S, Sekar T, Paulmurugan R, Scicinski J, Oronsky B, Peehl D, Knox S.
Proceedings: AACR 105th Annual Meeting 2014– Apr 5-9, 2014; San Diego, CA, Abstr 906

Presentation & Abstract
Resensitization to previous chemotherapy with the novel hypomethylating anticancer agent RRx-001
Reid T, Knox S, Ning S, Peehl D, Oronsky B, Stephens J, Fanger G, Korn R, Dad S, Scicinski J.
16th International Symposium on Anti-Angiogenic Therapy, La Jolla, Feb 6 – 8, 2014

Presentation & Abstract
High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain’
Fitch B, McLaughlin T, Fens M, Scicinski J.
2013 American Chemical Society, Western Regional Meeting, Abstract WRM 267 (Oral presentation)

Presentation & Abstract
Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent’
Reid T, Infante J, Paul A, Burris H, Oronsky B, Scribner C, Knox S, Stephens J, Santini J, Scicinski J.
Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1 (LB-86)
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC
Also presented at: 15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013

Presentation & Abstract
RRx-001: A novel hypoxia activated nitric oxide generating vascular disrupting agent (VDA)’
Oronsky B, Ning S, Knox S, Cabrales P, Minchinton A, Kuypers F, Fens M, Santini J, Reid T, Scicinski J.
15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013

Presentation & Abstract
Antivascular activity of RRx-001 in SCCVII and U87 tumors’
Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S.
15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013

Presentation & Abstract
RRx-001, a hypoxia activated, nitric oxide generating cytotoxic agent: Phase 1 study results’
Scicinski J.
Presentation at 3rd International Workshop on Nitric Oxide in Cancer Therapy, May 31 – Jun3 1, 2013, Kingston Ontario

Presentation & Abstract
RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors’
Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S.
Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1 (4371)
Proceedings: AACR 103rd Annual Meeting 2012– Mar 31-Apr 4, 2012; Chicago, IL

Presentation & Abstract
Treatment with a novel dinitroazetidine, ABDNAZ, improves nitrite reductase activity of sickle red blood cells’
Fens M, Larkin S, Scicinski J, Fitch W, Oronsky B, Kuypers F.
Blood (ASH Annual Meeting Abstracts) 2012, 120: Abstract 3246

Presentation & Abstract
NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells’
Fens M, Larkin S, Morris C, Fitch W, Scicinski J, Oronsky B, Kuypers F.
Blood (ASH Annual Meeting Abstracts) 2011, 118: Abstract 2125

Presentation & Abstract
Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials’
Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox S.
Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, (676)
Proceedings: AACR 102nd Annual Meeting 2011– Apr 2-6, 2011; Orlando, FL

Presentation & Abstract
Disposition of 14C-RRx-001 in rats after a single intravenous administration and in blood from rats, dogs, monkeys, and humans’
Scicinski J, Oronsky B, Fitch W, Taylor M, Luo G, Musick T, Marini J, Adams C, Schicker M, Gohdes M, McKenzie D, Ridgewell R.
ISSX Annual meeting 2011, Abstract P81